You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: August 2020 to March 2026

AbstractFullPdf
Aug 2020562561225
Sep 202021421480
Oct 202010910944
Nov 2020666638
Dec 2020808037
Jan 2021777631
Feb 2021656538
Mar 2021575740
Apr 2021868640
May 2021515142
Jun 2021606042
Jul 2021515137
Aug 2021595946
Sep 2021979760
Oct 2021696949
Nov 2021787868
Dec 2021404229
Jan 2022606549
Feb 2022515741
Mar 2022747746
Apr 2022778033
May 2022667636
Jun 2022535522
Jul 2022495527
Aug 2022485031
Sep 2022606137
Oct 2022485040
Nov 2022404022
Dec 2022313110
Jan 2023424423
Feb 2023525316
Mar 2023383929
Apr 2023383817
May 2023494918
Jun 2023505021
Jul 2023626223
Aug 2023494916
Sep 2023424323
Oct 202313013018
Nov 202325525618
Dec 2023525223
Jan 2024616233
Feb 2024424330
Mar 2024727253
Apr 2024494941
May 2024585831
Jun 2024565716
Jul 2024636325
Aug 2024606026
Sep 20245656103
Oct 2024939350
Nov 2024585932
Dec 2024899044
Jan 2025828249
Feb 2025424239
Mar 2025505143
Apr 2025929244
May 2025727447
Jun 2025434315
Mar 2026110
Total447645302306